Trial · NCT01013649
Participant flow60
How many started, completed or left each group, period by period.
1 to 20 of 60
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Step | STARTED | Arm I (Gemcitabine Hydrochloride or Combination Chemotherapy) | 379 | |
| First Step | STARTED | Arm II (Gemcitabine Hydrochloride, Erlotinib Hydrochloride) | 167 | |
| First Step | STARTED | Arm III (Chemotherapy) | 0 | |
| First Step | STARTED | Arm IV (Chemotherapy, Chemoradiotherapy) | 0 | |
| First Step | Randomized to Arm I or Arm II | Arm I (Gemcitabine Hydrochloride or Combination Chemotherapy) | 169 | |
| First Step | Randomized to Arm I or Arm II | Arm II (Gemcitabine Hydrochloride, Erlotinib Hydrochloride) | 167 | |
| First Step | Randomized to Arm I or Arm II | Arm III (Chemotherapy) | 0 | |
| First Step | Randomized to Arm I or Arm II | Arm IV (Chemotherapy, Chemoradiotherapy) | 0 | |
| First Step | Registered to Arm 1 Only | Arm I (Gemcitabine Hydrochloride or Combination Chemotherapy) | 210 | |
| First Step | Registered to Arm 1 Only | Arm II (Gemcitabine Hydrochloride, Erlotinib Hydrochloride) | 0 | |
| First Step | Registered to Arm 1 Only | Arm III (Chemotherapy) | 0 | |
| First Step | Registered to Arm 1 Only | Arm IV (Chemotherapy, Chemoradiotherapy) | 0 | |
| First Step | Eligible | Arm I (Gemcitabine Hydrochloride or Combination Chemotherapy) | 363 | |
| First Step | Eligible | Arm II (Gemcitabine Hydrochloride, Erlotinib Hydrochloride) | 159 | |
| First Step | Eligible | Arm III (Chemotherapy) | 0 | |
| First Step | Eligible | Arm IV (Chemotherapy, Chemoradiotherapy) | 0 | |
| First Step | Phase II Analysis Population | Arm I (Gemcitabine Hydrochloride or Combination Chemotherapy) | 163 | |
| First Step | Phase II Analysis Population | Arm II (Gemcitabine Hydrochloride, Erlotinib Hydrochloride) | 159 | |
| First Step | Phase II Analysis Population | Arm III (Chemotherapy) | 0 | |
| First Step | Phase II Analysis Population | Arm IV (Chemotherapy, Chemoradiotherapy) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01013649/flow